A polyvalent aptamer system for targeted drug delivery

Biomaterials. 2013 Dec;34(37):9728-35. doi: 10.1016/j.biomaterials.2013.08.079. Epub 2013 Sep 14.

Abstract

Poor efficacy and off-target systemic toxicity are major problems associated with current chemotherapeutic approaches to treat cancer. We developed a new form of polyvalent therapeutics that is composed of multiple aptamer units synthesized by rolling circle amplification and physically intercalated chemotherapy agents (termed as "Poly-Aptamer-Drug"). Using a leukemia cell-binding aptamer and doxorubicin as a model system, we have successfully constructed Poly-Aptamer-Drug systems and demonstrated that the Poly-Aptamer-Drug is significantly more effective than its monovalent counterpart in targeting and killing leukemia cells due to enhanced binding affinity (≈ 40 fold greater) and cell internalization via multivalent effects. We anticipate that our Poly-Aptamer-Drug approach will yield new classes of tunable therapeutics that can be utilized to effectively target and treat cancers while minimizing the side effects of chemotherapy.

Keywords: Aptamer; Cancer; Drug delivery; Leukemia; Multivalency; Rolling circle amplification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Antibiotics, Antineoplastic / pharmacology
  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / metabolism*
  • Base Sequence
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Doxorubicin / administration & dosage*
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism*
  • Drug Delivery Systems*
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / metabolism

Substances

  • Antibiotics, Antineoplastic
  • Aptamers, Nucleotide
  • Drug Carriers
  • Doxorubicin